Clinical Trial Update: Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413) [Phase 1]

View source ↗

Summary

Phase 1 Cognition Platform study of MK-0000-413 in participants at risk for Alzheimer's disease, with the trial completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• MK-0000-413

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Alzheimer's Disease, Mild Cognitive Impairment | Phase 1 | Status: COMPLETED | Results posted: 2024-10-28